FDA Approves Treatment for a Symptomatic Joint-Tumor Condition

Reporting by U.S. Food and Drug Administration · November 10, 2026

The FDA approved pimicotinib for adults with symptomatic tenosynovial giant cell tumor when surgery could worsen function or cause severe complications. The agency’s notice describes the trial and safety warnings, providing the approved use rather than a recommendation for individual patients.

This is HUB News’s original summary. Read the complete report at U.S. Food and Drug Administration.